In 13 patients with BRAF V600–mutant glioma treated with trametinib the estimated 24-month DOR rate was 100% for monotherapy and a median DOR of 33.6 months [95% CI, 11.2 to not reached (NR)] and estimated 24-month DOR rate of 80% (95% CI, 20–100) for those with dabrafenib and trametinib combination therapy (107). The gene discussed is BRAF; the disease is central nervous system cancer.